Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Universal Omics logo — We accelerate the process of discovering antiarrhythmic drug...

Universal Omics

We accelerate the process of discovering antiarrhythmic drugs through our innovative deep learning based technology DRUP

Founded 2021 Spain Spain 1 employees

General Information

Company Name Universal Omics
Founded Year 2021
Location Spain Spain +1
Employees 1
Social

Get notified when Universal Omics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Universal Omics

Universal Omics, founded in 2021 and based in Spain, stands out in the biotechnology industry with its innovative deep learning-based technology, DRUP (Drug Predictor). Positioned as a leader in drug design and analysis for cardiac disease and metabolic impairments, the company's focus on repairing and regulating the cell membrane uniquely equips it to address global health challenges. With a team of biotechnology and AI experts, Universal Omics aims to tackle the unmet needs in non-communicable disease treatment, especially arrhythmia. Given that around 18 million people annually succumb to cardiovascular diseases, where 15-20% of deaths are attributed to arrhythmias, the market demand for effective solutions is evident. The company's proprietary deep learning tool, DRUP-Drug Predictor, provides a competitive advantage by enabling precise prediction of molecule efficacy under varied conditions and doses. This not only expedites drug development but also ensures product safety and efficacy. Additionally, Universal Omics offers specialized services through DRUP-Drug Predictor software, including high throughput screening of bioactives, analysis of existing drugs and nutraceuticals, and design of new or redesigned drugs. Their mission revolves around providing innovative, personalized solutions to drive advancements in non-communicable disease treatment, focusing on the absence of adverse effects in the medium and long term. While there is no specific mention of the last investment or investors, Universal Omics showcases potential for partnerships in advancing more effective and safer treatments. As they continue to accelerate drug discovery with DRUP, the company presents an intriguing opportunity for strategic collaboration in transforming the healthcare landscape. For those seeking such partnerships, reaching out to info@universal-omic can pave the way for revolutionary advancements in healthcare.

Taxonomy: AI-powered biotech, nutraceutical drugs, metabolic dysfunctions, in silico drug design, deep learning, convolutional neuronal networks, omics data analysis, biomarker identification, therapeutical targets, personalized medicine, nutrient analysis, drug development, pre-clinical studies, clinical trials, pharmacology

No funding data available for Universal Omics yet.

Get notified when Universal Omics raises funding

FAQ About Universal Omics

We accelerate the process of discovering antiarrhythmic drugs through our innovative deep learning based technology DRUP
Universal Omics was founded in 2021.
Universal Omics is headquartered in Spain.
Universal Omics has approximately 1 employees.

We're actively collecting intelligence on Universal Omics.

Track Universal Omics to get notified

Don't just browse. Track.

Signal Tracker monitors Universal Omics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy